On a GLP-1? The next twelve months decide what you keep

The medication is working. The scale is moving. But not all of what comes off is fat.

Across the large semaglutide and tirzepatide trials, roughly a quarter to two-fifths of the weight lost on a GLP-1 is lean tissue: muscle and bone, not fat. For most people that share sits around 25 to 40 percent. The drug does not distinguish between the tissue you want gone and the tissue that carries you up stairs at sixty. Muscle is the body's largest metabolic organ and the single clearest marker of how independently a person ages. Lose it quietly now, and the version of you on the other side of the medication is lighter, but weaker, slower to recover, and harder to rebuild.

This is not a reason to stop the medication. It is the reason to train while you are on it.

The evidence is consistent: resistance training during medical weight loss protects lean tissue that would otherwise be lost, and in supervised programmes can build it back. The medication does what it does. Strength, posture, bone density, balance, the way you carry yourself into a room at fifty-five, the drug builds none of that. The work does. Catalyst is a healthspan and longevity focused studio. A smaller number on the scale can come with the work; what we train for is keeping what matters for the decades. We measure where you actually stand across four pillars, then build the next twelve months around protecting and growing your strength while the medication handles the fat.

Catalyst Performance was built on a method designed to be defensible to a doctor. Co-founders Bervin Manoharan and Jeremy Soh lead the studio and its coaching standards. Co-founder Dr Luqman Haris (MBBS), Head of Training Systems, leads the evidence base behind every programme. Every recommendation we make is one we can cite. The starting point is the Catalyst Healthspan Assessment: sixty minutes in studio, four pillars measured, a clear read on where your body stands today.